Kodiak Sciences Inc (KOD): Price and Financial Metrics
GET POWR RATINGS... FREE!
KOD Stock Price Chart Interactive Chart >
KOD Price/Volume Stats
| Current price | $6.92 | 52-week high | $26.39 |
| Prev. close | $6.72 | 52-week low | $4.90 |
| Day low | $6.50 | Volume | 751,200 |
| Day high | $6.92 | Avg. volume | 2,127,946 |
| 50-day MA | $6.79 | Dividend yield | N/A |
| 200-day MA | $14.38 | Market Cap | 359.52M |
Kodiak Sciences Inc (KOD) Company Bio
Kodiak Sciences is a clinical stage biopharma specializing in therapeutics to treat chronic retinal diseases. The company was founded in 2005 and is based in New York City, New York.
Latest KOD News From Around the Web
Below are the latest news stories about Kodiak Sciences Inc that investors may wish to consider to help them evaluate KOD as an investment opportunity.
Kodiak sheds over $2B market cap after wet AMD setback for lead assetKodiak Sciences (KOD -79.8%), a clinical-stage biotech focused on eye diseases, has lost more than $2B of its market capitalization on Wednesday after the company said its lead asset KSI-301 did not meet the primary endpoint in a Phase 2b/3 trial for wet age-related macular degeneration. The 559-patient study was... |
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, trader! |
Peninsula biotech stock loses 80% after eye drug's late-stage study failsThe company — which still has a quartet of late-stage trials with the drug and more than $700 million in cash — saw its stock continue to drop on Thursday. |
Why Kodiak Sciences Stock Is Cratering TodayWhat happened Shares of the clinical-stage biotech Kodiak Sciences (NASDAQ: KOD) are down by a hefty 80.3% as of 2:22 p.m. ET Wednesday afternoon. The drugmaker's stock is plunging today in response to its lead product candidate, KSI-301, failing to meet the primary endpoint of a combined phase 2/3 trial as a treatment for wet age-related macular degeneration (wet AMD). |
KOD Price Returns
| 1-mo | 14.38% |
| 3-mo | -21.54% |
| 6-mo | -63.30% |
| 1-year | -58.62% |
| 3-year | 248.09% |
| 5-year | N/A |
| YTD | -59.19% |
| 2021 | -42.29% |
| 2020 | 104.18% |
| 2019 | 913.38% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...